
Research view
Title: | Black-box warning and psychiatric drugs: a problem or a solution? |
Author: | Ghada Abdelrazek Mohammed Hassan |
Abstract: |
Recently, there is growing concern among psychiatrists regarding the increase in the
black-box warning for psychiatric medications, as 794 unique drugs were approved by
the Food and Drug Administration. Thirty-five percent (279) of these had a boxed
warning, the most severe label associated with adverse drug reactions. The aim of this
review was to search for the causes of warning for psychiatric medications and how to
remedy this problem. In addition, we aimed to determine the effect of these warnings
on our practice with regard to current drug regulations in Egypt. A search in the
Pubmed, MD consult, About.com, andWebMD Health News was carried out. Relevant
articles were reviewed. In the last 10 years, most psychiatric drugs have received
black-box warnings even for a class of drugs rather than just individual drugs. The laws
in Egypt necessitate that all psychiatrists should be up to date in their knowledge
about pharmacotherapy, adverse drug reactions, and recent studies on the efficacy
and safety of our drugs to advance the future of mental health. In addition, we have to
establish our own consensus and drug regulations on the basis of local researches
supported by the Ministry of health, education and research.
|
Journal: | Middle East Current Psychiatry 2012, 19:67–70 |
Text: | |
download |